Investment Success in Public Health: An Analysis of the Cost-Effectiveness and Cost-Benefit of the Global Programme to Eliminate Lymphatic Filariasis

Clinical Infectious Diseases

Volumn 64, Issue 6, 2017, Pages 728-735

  Turner, Hugo C ^a,b,c,d   Bettis, Alison A ^a,b   Chu, Brian K ^e   McFarland, Deborah A ^f   Hooper, Pamela J ^e   Mante, Sunny D ^g   Fitzpatrick, Christopher ^h   Bradley, Mark H ⁱ  

^a London Centre for Neglected Tropical Disease Research   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e Task Force for Global Health   (United States)

^f EMORY UNIVERSITY   (United States)

^g 37 Military Hospital ^*  (Ghana)

^h WORLD HEALTH ORGANIZATION   (Switzerland)

ⁱ GLAXOSMITHKLINE   (United Kingdom)

Author keywords

cost benefit; economic evaluation; hydrocelectomy; lymphatic filariasis; preventive chemotherapy

Indexed keywords

ANTHELMINTIC AGENT;

CHEMOPROPHYLAXIS; COST BENEFIT ANALYSIS; ECONOMICS; GLOBAL HEALTH; HEALTH CARE COST; HUMAN; INVESTMENT; LYMPHATIC FILARIASIS; OUTCOME ASSESSMENT; PUBLIC HEALTH; STATISTICS AND NUMERICAL DATA;

ANTHELMINTICS; CHEMOPREVENTION; COST-BENEFIT ANALYSIS; ELEPHANTIASIS, FILARIAL; GLOBAL HEALTH; HEALTH CARE COSTS; HUMANS; INVESTMENTS; OUTCOME ASSESSMENT (HEALTH CARE); PUBLIC HEALTH;

EID: 85038641316     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw835     Document Type: Article

References (29)

1. Ottesen EA. Lymphatic filariasis: treatment, control and elimination. Adv Parasitol 2006; 61:395–441.
2. Ottesen EA, Hooper PJ, Bradley M, Biswas G. The global programme to eliminate lymphatic filariasis: health impact after 8 years. PLoS Negl Trop Dis 2008; 2:e317.
3. Addiss DG, Brady MA. Morbidity management in the Global Programme to Eliminate Lymphatic Filariasis: a review of the scientific literature. Filaria J 2007; 6:2.
4. WorldHealthOrganization.GlobalProgrammetoEliminateLymphaticFilariasis: progress report 2000–2009 and strategic plan 2010–2020. 2010. Available at: http://www.searo.who.int/entity/vector_borne_tropical_diseases/topics/lymphatic_filariasis/LFREP.pdf
5. World Health Organization. Accelerating work to overcome the global impact of neglected tropical diseases—A roadmap for implementation. Available at: http://www.who.int/neglected_diseases/NTD_RoadMap_2012_Fullversion.pdf.
6. World Health Organization. 489 Global programme to eliminate lymphatic filariasis: progress report, 2014. Wkly Epidemiol Rec 2015; 90(38): 489–504.
7. World Health Organization. Investing to overcome the global impact of neglected tropical diseases: third WHO report on neglected tropical diseases. 2015. Available at: http://www.who.int/neglected_diseases/9789241564861/en/
8. Turner HC, Bettis AA, Chu BK, McFarland DA, Hooper PJ, Ottesen EA, Bradley MH. The health and economic benefits of the global programme to eliminate lymphatic filariasis (2000–2014). Infect Dis Poverty 2016; 5:54.
9. Fitzpatrick C, Fleming FM, Madin-Warburton M, Schneider T, Meheus F, Asiedu K, Solomon AW, Montresor A, Biswas G. Benchmarking the Cost per Person of Mass Treatment for Selected Neglected Tropical Diseases: An Approach Based on Literature Review and Meta-regression with Web-Based Software Application. PLoS Negl Trop Dis 2016;10:e0005037.
10. Benchmarks for the cost per person of mass treatment against neglected tropical diseases. Available at: https://healthy.shinyapps.io/benchmark.
11. US. Bureau of Labor Statistics: CPI Inflation Calculator. Available at: http://www.bls.gov/data/inflation_calculator.htm
12. World Health Organisation. PCT databank: Lymphatic filariasis. Available at: http://www.who.int/neglected_diseases/preventive_chemotherapy/lf/en/.
13. Kiddoo DA, Wollin TA, Mador DR. A population based assessment of complications following outpatient hydrocelectomy and spermatocelectomy. J Urol 2004; 171:746–8.
14. Ahorlu CK, Dunyo SK, Asamoah G, Simonsen PE. Consequences of hydrocele and the benefits of hydrocelectomy: a qualitative study in lymphatic filariasis endemic communities on the coast of Ghana. Acta Trop 2001; 80:215–21.
15. World Bank. World Development Report 1993: Investing in Health. New York: Oxford University Press, 1993.
16. Coffeng LE, Stolk WA, Zouré HGM, et al. African Programme for Onchocerciasis Control 1995–2015: Model-Estimated Health Impact and Cost. PLoS Negl Trop Dis 2013; 7(1): e2032.
17. WHO-CHOICE. Threshold values for intervention cost-effectiveness by region. Available at: http://www.who.int/choice/costs/CER_levels/en/.
18. World Health Organization Press Office. WHO, Smithkline Beechamto cooperate on Elephatiasis elmination. Available at: http://www.filariasis.org/pdfs/Press%20Centre/Press%20Release%20Archive/GSKpressrelease_Jan98.pdf
19. Ton TG, Mackenzie C, Molyneux DH. The burden of mental health in lymphatic filariasis. Infect Dis Poverty 2015; 4:34.
20. McFarland D, Menzies N, Njoumemi Z, Onwujekwe O. Study of cost per treatment with ivermectin using the CDTI strategy. African Programme for Onchocerciasis Control (APOC). 2005.
21. Stone CM, Kastner R, Steinmann P, Chitnis N, Tanner M, Tediosi F. Modelling the health impact and cost-effectiveness of lymphatic filariasis eradication under varying levels of mass drug administration scale-up and geographic coverage. BMJ Global Health 2016; 1: e000021.
22. Stillwaggon E, Sawers L, Rout J, Addiss D, Fox L. Economic costs and benefits of a community-based lymphedema management program for lymphatic filariasis in Odisha State, India. Am J Trop Med Hyg 2016; 95:877–84.
23. Thomsen EK, Sanuku N, Baea M, et al. Efficacy, safety, and pharmacokinetics of coadministered diethylcarbamazine, albendazole, and ivermectin for treatment of bancroftian filariasis. Clin Infect Dis 2016; 62:334–41.
24. Newall AT, Jit M, Hutubessy R. Are current cost-effectiveness thresholds for low- and middle-income countries useful? Examples from the world of vaccines. Pharmacoeconomics 2014; 32:525–31.
25. Marseille E, Larson B, Kazi DS, Kahn JG, Rosen S. Thresholds for the cost-effectiveness of interventions: alternative approaches. Bull World Health Organ 2015; 93:118–24.
26. Shillcutt SD, Walker DG, Goodman CA, Mills AJ. Cost effectiveness in low- and middle-income countries: a review of the debates surrounding decision rules. Pharmacoeconomics 2009; 27:903–17.
27. Conteh L, Engels T, Molyneux DH. Socioeconomic aspects of neglected tropical diseases. Lancet 2010; 375:239–47.
28. Turner HC, Walker M, French MD, Blake IM, Churcher TS, Basáñez MG. Neglected tools for neglected diseases: mathematical models in economic evaluations. Trends Parasitol 2014; 30:562–70.
29. Liese BH, Houghton N, Teplitskaya L. Development assistance for neglected tropical diseases: progress since 2009. Int Health 2014; 6:162–71.